Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Refametinib

Drug Profile

Refametinib

Alternative Names: AR-119; BAY-86-9766; RDEA-119; VRX-119

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Valeant Pharmaceuticals International
  • Developer Ardea Biosciences; Bayer HealthCare; Samsung Medical Center
  • Class Aniline compounds; Anti-inflammatories; Antineoplastics; Small molecules; Sulfonamides
  • Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Biliary cancer; Liver cancer
  • Phase I/II Pancreatic cancer; Solid tumours
  • Discontinued Inflammation

Most Recent Events

  • 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
  • 24 Jun 2018 Biomarkers information updated
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease) in Netherlands (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top